FcRγ-Deficient NK Cell Expansion for Low-Abundance Subsets

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

The low abundance of specialized subsets of natural killer (NK) cells in human peripheral blood and the lack of surface phenotypic features poses a challenge for their application in therapeutic methods, particularly in adoptive cell therapy.

Innovation Solution

A method for expanding FcRγ-deficient NK cells by isolating specific subsets from human subjects and culturing them with irradiated feeder cells and recombinant IL-2, using ratios and conditions that enhance their expansion, optionally with additional stimulatory agents and PBMC feeder cells.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Quantity of substance

If conventional NK cell isolation methods are used, then NK cells can be obtained, but their abundance remains low and specialized subsets cannot be sufficiently enriched

Engineering Contradiction:
ImproveNK cell abundanceVSAvoidsurface phenotypic features
Core Design Contradiction:
Quantity of substanceVSDifficulty of detecting and measuring

Solution Approach 1:

The patent segments the NK cell population into specialized subsets based on specific surface marker profiles (CD3negCD56posCD38neg, CD3negCD57pos, etc.), enabling selective isolation and expansion of particular functional subsets rather than treating all NK cells as a homogeneous population

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

The patent introduces irradiated 221.AEH feeder cells as an intermediary component in the culture system. These feeder cells provide necessary growth signals and support the expansion of specialized NK cell subsets when combined with recombinant IL-2, overcoming the limitation of low abundance without requiring complex detection methods

Inventive Principle:
Principle #24Intermediary (Mediator)

2Productivity

If standard culturing conditions are used, then NK cells can be maintained, but significant expansion of specialized subsets is not achieved

Engineering Contradiction:
ImproveNK cell expansionVSAvoidculture conditions
Core Design Contradiction:
ProductivityVSDevice complexity

Solution Approach 1:

The patent changes key culture parameters including the addition of irradiated 221.AEH feeder cells at specific ratios (1:10 to 10:1), optimization of recombinant IL-2 concentration, and selection of specific NK cell subsets based on surface markers. These parameter changes enable up to 1000-fold expansion of specialized NK cell subsets

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The irradiated 221.AEH feeder cells provide self-service by secreting necessary growth factors and cytokines that support NK cell expansion, reducing the need for complex external intervention while achieving significant productivity improvement

Inventive Principle:
Principle #25Self-service

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The method achieves a significant expansion of FcRγ-deficient NK cells, increasing their numbers by up to 1000-fold, providing a viable therapeutic population for treating diseases like cancer.

Implementation Method 1

culturing the population of enriched NK cells in the presence of (i) irradiated 221.AEH feeder cells

Methodology Applied
Scientific EffectCell culture:

Implementation Method 2

culturing the population of enriched NK cells in the presence of (i) irradiated 221.AEH feeder cells and (ii) recombinant IL-2

Methodology Applied
Scientific EffectCytokine signaling:

Implementation Method 3

culturing the population of enriched NK cells in the presence of (i) irradiated 221.AEH feeder cells and (ii) recombinant IL-2, wherein the method produces an expanded population of g-NK cells

Methodology Applied
Scientific EffectCytokine signaling:

Data Source

PatentUS12410402B2Methods for expansion of natural killer (NK) cell subset and related compositions and methods
Publication Date: 2025.09.09 INDAPTA THERAPEUTICS INC
  • US12410402B2 patent drawing
  • US12410402B2 patent drawing
  • US12410402B2 patent drawing

AI summary

Provided herein are methods for ex vivo expansion of a specialized subset of natural killer (NK) cells, and compositions containing such NK cells. Also provided are methods for identifying or detecting a specialized subset of NK cells. Also provided are methods for treating diseases and conditions such as cancer using provided compositions, including in combination with an antibody capable of binding to disease-associated tissues or cells, such as tumor cells or infected cells.